Vaxart Inc
VXRT0.320USD
-0.107-25.06%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
73.03MCap. mercado
PérdidaP/E TTM
Más Datos de Vaxart Inc Compañía
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Información de la empresa
Símbolo de cotizaciónVXRT
Nombre de la empresaVaxart Inc
Fecha de salida a bolsaMar 17, 1980
Director ejecutivoMr. Steven (Steve) Lo
Número de empleados105
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 17
Dirección170 Harbor Way, Suite 300
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresUS 'Other OTC' and Grey Market
PaísUnited States of America
Código postal94080
Teléfono16505503500
Sitio Webhttps://vaxart.com/
Símbolo de cotizaciónVXRT
Fecha de salida a bolsaMar 17, 1980
Director ejecutivoMr. Steven (Steve) Lo
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Edward B. Berg
Mr. Edward B. Berg
Senior Vice President, General Counsel
Senior Vice President, General Counsel
435.74K
+1053.17%
Mr. Jeroen Grasman
Mr. Jeroen Grasman
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
350.00K
--
Dr. Elaine J. Heron, Ph.D.
Dr. Elaine J. Heron, Ph.D.
Independent Director
Independent Director
51.65K
+44.88%
Mr. Steven (Steve) Lo
Mr. Steven (Steve) Lo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.14K
-97.54%
Dr. Sean N. Tucker, Ph.D.
Dr. Sean N. Tucker, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Mr. W. Mark Watson
Mr. W. Mark Watson
Independent Director
Independent Director
--
--
Dr. James F. Cummings, M.D.
Dr. James F. Cummings, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Matt Stein
Matt Stein
IR Contact Officer
IR Contact Officer
--
--
Mr. Kevin P. Finney
Mr. Kevin P. Finney
Independent Director
Independent Director
--
--
Ms. Laurie Hastings
Ms. Laurie Hastings
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Edward B. Berg
Mr. Edward B. Berg
Senior Vice President, General Counsel
Senior Vice President, General Counsel
435.74K
+1053.17%
Mr. Jeroen Grasman
Mr. Jeroen Grasman
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
350.00K
--
Dr. Elaine J. Heron, Ph.D.
Dr. Elaine J. Heron, Ph.D.
Independent Director
Independent Director
51.65K
+44.88%
Mr. Steven (Steve) Lo
Mr. Steven (Steve) Lo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
40.14K
-97.54%
Dr. Sean N. Tucker, Ph.D.
Dr. Sean N. Tucker, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Mr. W. Mark Watson
Mr. W. Mark Watson
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 23 de may
Actualizado: vie., 23 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
4.54%
Sio Capital Management, LLC
2.45%
Geode Capital Management, L.L.C.
1.17%
BlackRock Institutional Trust Company, N.A.
0.78%
Millennium Management LLC
0.42%
Other
90.64%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
4.54%
Sio Capital Management, LLC
2.45%
Geode Capital Management, L.L.C.
1.17%
BlackRock Institutional Trust Company, N.A.
0.78%
Millennium Management LLC
0.42%
Other
90.64%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
6.33%
Hedge Fund
3.23%
Investment Advisor/Hedge Fund
2.18%
Individual Investor
1.35%
Research Firm
0.26%
Pension Fund
0.05%
Bank and Trust
0.02%
Family Office
0.01%
Other
86.57%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
223
30.63M
13.42%
-33.98M
2025Q1
260
32.73M
14.34%
-33.64M
2024Q4
273
38.15M
16.82%
-29.38M
2024Q3
304
39.77M
17.54%
-31.47M
2024Q2
307
43.16M
19.03%
-9.14M
2024Q1
311
42.29M
24.34%
-1.37M
2023Q4
307
17.70M
11.60%
-12.17M
2023Q3
319
19.94M
13.09%
-20.38M
2023Q2
329
30.49M
20.10%
-12.31M
2023Q1
343
36.99M
27.31%
-14.55M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
10.37M
4.54%
+291.51K
+2.89%
Mar 31, 2025
Sio Capital Management, LLC
5.58M
2.45%
-5.93M
-51.51%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.66M
1.17%
+58.98K
+2.27%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.78M
0.78%
-9.61K
-0.54%
Mar 31, 2025
Millennium Management LLC
955.87K
0.42%
-2.03M
-68.04%
Mar 31, 2025
Squarepoint Capital LLP
804.48K
0.35%
+287.68K
+55.67%
Mar 31, 2025
State Street Global Advisors (US)
790.25K
0.35%
+101.40K
+14.72%
Mar 31, 2025
Finney Michael J
702.84K
0.31%
+16.00K
+2.33%
Jun 13, 2025
SilverArc Capital Management, LLC
683.83K
0.3%
-393.96K
-36.55%
Mar 31, 2025
Lee (Phillip E.)
631.62K
0.28%
+397.95K
+170.31%
Mar 24, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco RAFI US 1500 Small-Mid ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
Fidelity Nasdaq Composite Index ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
